Explore Intellia Therapeutics, Inc.'s outlook after Phase 3 trial concerns. See how FDA decisions may impact CRISPR therapy ...
2023 was the year that CRISPR gene-editing sliced its way out of the lab and into the public consciousness—and American medical system. The Food and Drug Administration recently approved the first ...
CRISPR Therapeutics (NASDAQ:CRSP) gains visibility as biotechnology activity aligns with broader movements across the Nasdaq ...
Crisp Therapeutics received regulatory authorization for the first CRISPR/Cas9 gene-edited therapy in the world. Crispr shares were up close to 5% on the news. Don’t miss this list of 3 high-yield ...
Deep-pocketed investors have adopted a bearish approach towards CRISPR Therapeutics (NASDAQ:CRSP), and it's something market players shouldn't ignore. Our tracking of public options records at ...
When blood cancer in children progresses particularly aggressively, it is often due to a genetic defect: a gene fusion, such ...
Crispr shares are trading higher Thursday after Wolfe Research initiated coverage on Crispr Therapeutics with a Peer Perform rating. Crispr Therapeutics' shares rise nearly 37% over the past month ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback